Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sigyn Therapeutics Inc (OP:SIGY)

0.0350 +0.0021 (+6.38%)
Delayed Quote Updated: 12:09 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sigyn Therapeutics Inc

< Previous 1 2 3 4 Next >
Sigyn Therapeutics Inc. (SIGY) Therapeutic Candidates to Overcome Limitations in Healthcare
Via Investor Brand Network
Sigyn Therapeutics Inc. (SIGYD) Completes Reverse Stock Split, Releases Year-End Financial Report for 2023
Via Investor Brand Network
News headline image
Sigyn Therapeutics Announces Filing of 2023 Annual Report on SEC Form 10-K
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split
Via Investor Brand Network
Topics Death
News headline image
Sigyn Therapeutics Completes Reverse Stock Split
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) to Implement 1-for-40 Reverse Split
Via Investor Brand Network
Topics Death
Sigyn Therapeutics Announces Reverse Stock Split
SAN DIEGO, CA - (NewMediaWire) - January 30, 2024 - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced that a 1-for-40... 
Via NewMediaWire
Sigyn Therapeutics Announces Reverse Stock Split
SAN DIEGO, CA - (NewMediaWire) - January 30, 2024 - Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today announced that a 1-for-40... 
Via TheNewswire.com
BioMedNewsBreaks — Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’
Via Investor Brand Network
Topics Death
Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks – Sigyn Therapeutics Inc. (SIGY) CEO Releases Shareholder Letter Outlining Opportunities, Challenges, Processes
Via Investor Brand Network
Topics Death
News headline image
Sigyn Therapeutics Releases Letter to Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
News headline image
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Sigyn Therapeutics Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death Economy Intellectual Property
News headline image
Sigyn Therapeutics to Present at Today's Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Sigyn Therapeutics to Present at Tomorrow's Emerging Growth Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
OTCQB Venture Virtual Investor Conference Agenda Announced for August 3rd
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd
The Company invites analysts, individual and institutional investors to participate online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrepTM Trademark Application
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Sigyn Therapeutics Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
News headline image
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
Sigyn Therapeutics Discloses Trademark Applications to Register ChemoPrepTM and ChemoPureTM for Devices to Enhance Cancer Therapy
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
Sigyn Therapeutics Announces Cancer-Related Patent Submission Entitled: System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
Sigyn Therapeutics Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.